Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.56%
#2 Luxxcoin Luxxcoin +46.85%
#3 Layer3 Layer3 +32.82%
#4 ResearchCoin ResearchCoin +31.78%
#5 Reactive Network Reactive Network +24.01%
#6 Orderly Network Orderly Network +17.27%
#7 Bitgert Bitgert +17.01%
#8 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +10.20%
#9 Useless Coin Useless Coin +10.11%
#10 OpenVPP OpenVPP +9.68%
Coin of the day
Resolv wstUSR Resolv wstUSR
Settings
Language
ENGLISH
Currency
USD
Theme
CSL Limited CSL Limited

CSL Limited

CSL
Rank in Stocks #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Share Price
$99.32
Market Cap
$48.20B
Change (1 day)
0.98%
Change (1 year)
-32.14%
Country
AU
Trade CSL Limited (CSL)

Category

Healthcare
Revenue for CSL Limited (CSL)
Revenue in Dec 2025 TTM: $15.70B
According to CSL Limited latest financial reports the company's current revenue (TTM) is $15.70B. In 2024 the company made a revenue of $14.69B an increase over the revenue in the year 2023 that was $13.17B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for CSL Limited from 2000 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $15.70B 1.72%
2025 $15.43B 5.04%
2024 $14.69B 11.51%
2023 $13.17B 25.55%
2022 $10.49B 1.56%
2021 $10.33B 9.84%
2020 $9.41B 13.08%
2019 $8.32B 11.54%
2018 $7.46B 6.28%
2017 $7.02B 15.81%
2016 $6.06B 11.00%
2015 $5.46B 8.91%
2014 $5.01B 10.79%
2013 $4.52B -2.44%
2012 $4.64B -3.37%
2011 $4.80B 49.63%
2010 $3.21B 6.25%
2009 $3.02B -7.53%
2008 $3.26B 42.87%
2007 $2.28B 45.52%
2006 $1.57B -1.58%
2005 $1.60B 98.59%
2004 $803.28M 36.45%
2003 $588.71M 38.88%
2002 $423.90M -2.21%
2001 $433.49M 0.00%
2000 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 209.32%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -23.30%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -8.62%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -42.13%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -65.01%
NL